期刊文献+

化学发光微粒子免疫法检测人附睾蛋白方法学性能评价 被引量:1

Methodological evaluation of chemiluminescence microparticle immunoassay for determining HE4
原文传递
导出
摘要 目的对Abbott Architect i2000SR检测系统应用化学发光微粒子免疫技术定量测定人附睾蛋白(HE4)的分析性能进行评价。方法参考美国临床实验室标准化协会(NCCLS)文件,制定定量检测方法的方法学评价方案,通过Abbott Architect i2000SR检测系统测定HE4的批内精密度、批间精密度、线性范围、携带污染率和参考区间。结果低、高值混合血清批内精密度CV分别为1.80%、2.34%;批间精密度CV分别为2.03%、2.70%;线性范围为19.8~1 573.5 pmol/L;携带污染率为-0.02%;参考区间为0.0~140.0 pmol/L。结论 Abbott Architecti2000SR检测系统测定HE4的精密度好、线性范围宽、携带污染率低,参考区间与厂家提供的一致,检测性能可满足临床要求。 Objective To evaluate the performance methodology of Chemiluminescence microparticle immunoassay (CMIA) for determining HE4 using Abbott Architect i2000SR Chemiluminescence analyzer. Methods According to a method by NCCLS recommended, we designed the evaluation program of quantitative detection methods. The within- run precision ,between-run precision ,linear range ,carry-over and biological reference interval of HFA were determined. Results The coefficient of variation (CV) of within-run precision of low and high value pooled serum were respectively 1.80% and 2.34%. The CV of between-run precision were respectively 2.03% and 2.70%. The linear range was from 19.8 pmoL/L to 1 573.5 pmol/L. The I carry-over was -0.02%. The biological reference interval was consistent with manufactures which is from 0.0 pmol/L to 140.0 pmol/L. Conclusion The within-run precision, between-run precision, linear range and carry-over of Abbott Architect i2000SR for determining HE4 meet the requirements of clinical use. The biological reference interval was consistent with that provided by the manufacturer.
出处 《山东大学学报(医学版)》 CAS 北大核心 2012年第10期73-76,共4页 Journal of Shandong University:Health Sciences
基金 卫生部国家临床重点专科建设项目
关键词 ABBOTT ARCHITECT i2000SR检测系统 化学发光微粒子免疫技术 人附睾蛋白4 方法学评价 Abbott architect i2000SR chemiluminescence analyzer CMIA HFA Methodological evaluation
  • 相关文献

参考文献17

  • 1Langm6r Z, N6meth M, Vlesk6 G, et al. HE4-a novel promising serum marker in the diagnosis of ovarian carci- noma[J].Eur J Gynaecol Oncol, 2011, 32 (6) : 605- 610. 被引量:1
  • 2Moore R G, Miller M C, Steinhoff M M, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders [ J]. Am J Ob- stet Gynecol, 2012, 206(4) :351. el-351, e8. 被引量:1
  • 3Partheen K, Kristjansdottir B, Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass [J]. J Gynecol Oncol, 2011, 22(4):244-252. 被引量:1
  • 4Kadija S, Stefanovic A, Jeremic K, et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endome- triosis[J].Int J Gynecol Cancer, 2012, 22(2):238- 94. 被引量:1
  • 5KongSY, HanMH, YooHJ, etal. SerumHE41evel is an independent prognostic factor in epithelial ovarian cancer[J]. Ann Surg Oncol, 2012, 19(5) :1707-1712. 被引量:1
  • 6Hellstrom I, Hellstrom K E. fTwo novel biomarkers, me- sothelin and HE4, for diagnosis of ovarian carcinoma [J]. Expert Opin Med Diagn, 2011, 5 (3) :227-240. 被引量:1
  • 7Bignotti E, Ragnoli M, Zanotti L, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients [ J]. Br J Cancer, 2011, 104 ( 9 ) : 1418-1425. 被引量:1
  • 8王锋,廖予妹,王武亮,黄冬梅,樊冬梅.血清人附睾分泌蛋白4、癌胚抗原125联合检测诊断卵巢上皮性癌的价值[J].中华实用诊断与治疗杂志,2010,24(4):383-384. 被引量:8
  • 9刘国瑞,王艾丽,刘琦,经卉,李梅,严孝岭,虞伟,李晓军.联合检测血清CA125和HE4用于卵巢癌诊断及鉴别诊断[J].临床检验杂志,2010,28(2):119-121. 被引量:39
  • 10唐志坚,叶雪,昌晓红,崔恒.血清人附睾蛋白4在卵巢癌临床转归中的关系[J].中国妇产科临床杂志,2011,12(5):364-368. 被引量:10

二级参考文献67

共引文献126

同被引文献9

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部